Significantly improve renal function in diabetic patients, Janssen publicly updated clinical data

Significantly improve renal function in diabetic patients, Janssen publicly updated clinical data

April 13, 2018 Source: WuXi PharmaTech

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional analysis of the landmark CANVAS project, showing that INVOKANA® (canagliflozin) improves renal outcomes in patients with type 2 diabetes with high-risk cardiovascular disease. The data was presented at the 2018 National Kidney Foundation Spring Clinical Conference in Austin, Texas.

Diabetes is a growing global epidemic. As of 2015, 400 million adults worldwide are affected by diabetes. Diabetic nephropathy is an important complication of diabetes and has become one of the most common causes of end-stage renal disease. Due to its complex metabolic disorders, once it reaches the end stage, it is often more difficult to treat than other kidney diseases. Therefore, timely prevention and treatment is of great significance for delaying diabetic nephropathy.

Canagliflozin is a daily oral diabetes drug that belongs to the class of sodium glucose cotransporter 2 (SGLT2) inhibitors. These drugs reduce the body's blood sugar levels by blocking the kidney's reabsorption of blood sugar and increasing the excretion of blood sugar in the urine.

The CANVAS project is the longest and most extensive focus on cardiovascular efficacy in all SGLT2 inhibitors to date. It is also the first project to evaluate the efficacy, safety, and persistence of canagliflozin in more than 10,000 patients with type 2 diabetes who have a history of cardiovascular disease or at least two cardiovascular risk factors. In the new analysis, canagliflozin reduced the urinary albumin to creatinine ratio (UACR), a key biomarker for chronic kidney disease. In patients with renal function retention and reduction, glomerular filtration rate (eGFR) was reduced from baseline. 17% and 23% (P heterogeneity = 0.01). At pre-specified composite endpoints (40% reduction in eGFR, end-stage renal disease or nephropathy death), canagliflozin resulted in a 47% reduction in relative risk in patients with renal function retention (HR 0.53, 95% CI 0.39-0.73, P heterogeneity) =0.28), the risk was reduced by 24% in patients with reduced renal function (HR 0.76, 95% CI 0.49-1.17, P heterogeneity = 0.28). Similar results were observed in studies in which creatinine doubled instead of eGFR decreased by 40%. No new adverse events were observed in the study.

"Diabetes nephropathy remains the most common cause of end-stage renal disease worldwide, highlighting the need for further exploration of potential renal protection of SGLT2 inhibitors," said Dr. George Bakris, professor and director of the Center for Integrated Hypertension at the University of Chicago School of Medicine. The results of the analysis add a wealth of evidence that canagliflozin potentially improves kidney outcomes in millions of patients with type 2 diabetes, a benefit that can be observed in patients with preserved and reduced renal function."

“Although about one-third of people with diabetes have diabetic nephropathy, there is no significant improvement in treatment,” said Dr. James F. List, director of cardiovascular and metabolic global treatment at Janssen R&D. “We may be diabetic for canagliflozin. Nervous patients are encouraged by the much-needed benefits and look forward to further enhancing this insight in the complete patient recruitment and the first dedicated SGLT2 inhibitor test CREDENCE to assess renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy."

We look forward to seeing more positive data on this new type 2 diabetes drug in the future, bringing new treatments to the majority of diabetic patients as soon as possible.

Reference materials:

[1] INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

[2] Janssen official website

[3] WuXi PharmaTech - Janssen type 2 diabetes drugs significantly reduce the risk of cardiovascular death

Skin Repairing

We're well-known as one of the leading Cosmetic Raw material-Skin Repairing manufacturers and suppliers for our quality products and good service. Please feel free to buy or wholesale bulk centella asiatica, 5-ALA 5-Aminolevulinic acid, Paeoniflorin and Forskolin for sale at the best price from our factory.

Skin Repairing,Skin Repairing Cosmetic Raw Ingredients,Skin Repairing Extract Plant,Skin Repairing Cosmetic Powder

Xi'an Natural Field Bio-Technique Co., Ltd. , https://www.naturalnf.com